In order to develop the manufacturing process for Arovella’s ALA-101 product candidate—which is intended to treat cancer patients in upcoming clinical trials—Cell Therapies Pty Ltd has partnered with Arovella Therapeutics .
The ALA-101 product combines a Chimeric Antigen Receptor (CAR) that targets CD19 with Arovella’s invariant natural killer T (iNKT) cell treatment platform from Imperial College London. The allogeneic cell treatment ALA-101 is being developed to offer a “off-the-shelf” remedy for malignancies that express CD19.
Cell Therapies will further develop Arovella’s CAR-iNKT manufacturing process and advance it further in order to satisfy phase 1 clinical trial standards.